The GARDP Foundation (known as GARDP) and the privately-owned, global biopharmaceutical company Debiopharm today announced ...

Point-of-care testing for common sexually transmitted infections may reduce overuse of antibiotics and improve emergency ...

The GARDP Foundation and Debiopharm have entered a collaboration and license agreement to pursue the development of a novel, first-in-class antibiotic targeting Neisseria gonorrhoeae.

Artificial intelligence is revolutionizing antibiotic discovery, potentially tackling antibiotic-resistant bacteria and ...

OSUR files FDA applications seeking approval for two at-home STI tests, advancing decentralized diagnostics; shares gain 3.8% as it targets long-term growth.

Not only is gonorrhoea becoming increasingly common, but rising antibiotic resistance is making the once easily curable infection increasingly difficult to treat, reports Katharine Lang Drug resistant ...

Dutch biotech Intravacc has been given a $14.6 million grant by the US government to develop an intranasal vaccine for gonorrhoea, a sexually-transmitted infection that is on the rise around the world ...

As we look ahead to 2026, we are continuing to execute on our strategy with purpose and momentum to create value for all our stakeholders.” OTI’s rapid self-test for CT/NG is built on the Sherlock ...

Their specificity for the host is partly achieved by specific host adhesion mechanisms. As adhesins are required for the first step of colonization, they also constitute key virulence factors and have ...

Debio1453 is a first-in-class antibiotic candidate that targets an enzyme that’s essential for the growth of Neisseria ...

The FDA has given a fast-track designation to a gonorrhoea vaccine in development at GSK that could help turn the tide of the sexually-transmitted infection, which is on the rise around the world. The ...

The Bethlehem-based maker of at-home diagnostic tests said it submitted two separate applications to the FDA at the end of ...